Author

S. Ramon-Garcia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:drug response / drug discovery· 4 Organism:bacteria (other)· 3 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

J. A. Ainsa· 3 shared M. Gomara-Lomero· 3 shared A. I. Lopez-Calleja· 2 shared A. Rezusta· 2 shared A. C. Millan Placer· 1 shared A. L. Quintana· 1 shared A. Lucia Quintana· 1 shared A. Mendoza-Losana· 1 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. A. Ainsa

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans

E. Saez-Lopez, A. C. Millan Placer, A. L. Quintana, S. Ramon-Garcia

This study evaluates the in vitro bactericidal activity of amoxicillin/clavulanate combined with rifampicin/clarithromycin against Mycobacterium ulcerans and compares methodologies for bacterial load quantification.

bioRxiv · Dec 18, 2023 · PreprintMicrobiology

Repurposing azithromycin in combination with last-line fosfomycin, colistin and tigecycline against Multi-Drug Resistant Klebsiella pneumoniae

M. Gomara-Lomero, A. I. Lopez-Calleja, A. Rezusta, J. A. Ainsa, S. Ramon-Garcia

This study evaluates azithromycin combinations with last-line antibiotics against MDR/XDR K. pneumoniae, finding synergistic effects in all tested combinations.

bioRxiv · Jul 3, 2022 · PreprintMicrobiology

Zidovudine multi-combos with last-line fosfomycin, ceftazidime-avibactam, colistin and tigecycline against Multi-Drug Resistant Klebsiella pneumoniae

M. Gomara-Lomero, A. I. Lopez-Calleja, A. Rezusta, J. A. Ainsa, S. Ramon-Garcia

This study evaluates zidovudine-based combinations with last-line antibiotics against MDR K. pneumoniae, finding synergistic effects and potent bactericidal activity in vitro.

bioRxiv · May 17, 2022 · PreprintMicrobiology

Novel synergistic combinations of last-line antibiotics and FDA-approved drugs against Klebsiella pneumoniae revealed by in vitro synergy screenings

M. Gomara-Lomero, J. A. Ainsa, S. Ramon-Garcia

bioRxiv · May 16, 2022 · PreprintMicrobiology

The veterinary anti-parasitic selamectin is a novel inhibitor of the mycobacterial DprE1 enzyme

J. M. Ezquerra-Aznarez, G. Degiacomi, H. Gasparovic, G. Stelitano, J. C. Sammartino, J. Kordulakova, P. Governa, F. Manetti, M. R. Pasca, L. R. Chiarelli, S. Ramon-Garcia

This study identifies selamectin as an inhibitor of the mycobacterial DprE1 enzyme, showing susceptibility in mutants and docking predictions, but with conflicting results in phenotypic assays and metabolic labeling.

bioRxiv · Dec 4, 2021 · PreprintMicrobiology

Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

M. P. Arenaz Callao, R. Gonzalez del Rio, A. Lucia Quintana, C. J. Thompson, A. Mendoza-Losana, S. Ramon-Garcia

This study investigates the effectiveness of beta-lactam antibiotics in combination with existing drugs for treating Buruli ulcer, finding strong synergistic effects and significant MIC reductions.

bioRxiv · Oct 11, 2018Microbiology